Your browser doesn't support javascript.
loading
Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation.
Koczkowska, Magdalena; Callens, Tom; Gomes, Alicia; Sharp, Angela; Chen, Yunjia; Hicks, Alesha D; Aylsworth, Arthur S; Azizi, Amedeo A; Basel, Donald G; Bellus, Gary; Bird, Lynne M; Blazo, Maria A; Burke, Leah W; Cannon, Ashley; Collins, Felicity; DeFilippo, Colette; Denayer, Ellen; Digilio, Maria C; Dills, Shelley K; Dosa, Laura; Greenwood, Robert S; Griffis, Cristin; Gupta, Punita; Hachen, Rachel K; Hernández-Chico, Concepción; Janssens, Sandra; Jones, Kristi J; Jordan, Justin T; Kannu, Peter; Korf, Bruce R; Lewis, Andrea M; Listernick, Robert H; Lonardo, Fortunato; Mahoney, Maurice J; Ojeda, Mayra Martinez; McDonald, Marie T; McDougall, Carey; Mendelsohn, Nancy; Miller, David T; Mori, Mari; Oostenbrink, Rianne; Perreault, Sebastién; Pierpont, Mary Ella; Piscopo, Carmelo; Pond, Dinel A; Randolph, Linda M; Rauen, Katherine A; Rednam, Surya; Rutledge, S Lane; Saletti, Veronica.
Afiliação
  • Koczkowska M; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Callens T; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Gomes A; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Sharp A; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Chen Y; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Hicks AD; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Aylsworth AS; Departments of Pediatrics and Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Azizi AA; Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Basel DG; Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
  • Bellus G; Department of Clinical Genetics and Metabolism, Children's Hospital, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Bird LM; Department of Pediatrics, University of California San Diego; Division of Genetics/Dysmorphology, Rady Children's Hospital, San Diego, California, USA.
  • Blazo MA; Baylor Scott and White Hospital, Temple, Texas, USA.
  • Burke LW; Clinical Genetics Program, University of Vermont Medical Center, Burlington, Vermont, USA.
  • Cannon A; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Collins F; Department of Clinical Genetics, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
  • DeFilippo C; Department of Pediatrics, Division of Genomic Medicine, UC Davis MIND Institute, Sacramento, California, USA.
  • Denayer E; Department of Human Genetics, KU Leuven-University of Leuven, Leuven, Belgium.
  • Digilio MC; Medical Genetics Unit, Bambino Gesù Children's, IRCCS, Rome, Italy.
  • Dills SK; Carolinas Medical Center, Charlotte, North Carolina, USA.
  • Dosa L; SOC Genetica Medica, AOU Meyer, Florence, Italy.
  • Greenwood RS; Department of Neurology, Division of Child Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Griffis C; Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
  • Gupta P; Neurofibromatosis Diagnostic & Treatment Program, St. Joseph's Children's Hospital, Paterson, New Jersey, USA.
  • Hachen RK; Neurofibromatosis Program, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Hernández-Chico C; Department of Genetics, Hospital Universitario Ramón y Cajal, Institute of Health Research (IRYCIS), Madrid, Spain.
  • Janssens S; Center for Biomedical Research-Network of Rare Diseases (CIBERER), Madrid, Spain.
  • Jones KJ; Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
  • Jordan JT; Department of Clinical Genetics, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
  • Kannu P; Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Korf BR; Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Lewis AM; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Listernick RH; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
  • Lonardo F; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Mahoney MJ; Medical Genetics Unit, G. Rummo Hospital, Benevento, Italy.
  • Ojeda MM; Department of Genetics, Yale University, New Haven, Connecticut, USA.
  • McDonald MT; Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.
  • McDougall C; Department of Pediatrics, Division of Medical Genetics, Duke University School of Medicine, Durham, North Carolina, USA.
  • Mendelsohn N; Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Miller DT; Genomics Medicine Program, Children's Hospital Minnesota, Minneapolis, Minnesota, USA.
  • Mori M; Division of Genetics and Genomics, Boston Children's Hospital, Boston, Massachusetts, USA.
  • Oostenbrink R; Department of Pediatrics, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
  • Perreault S; Department of General Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands.
  • Pierpont ME; CHU Sainte-Justine, Mother and Child University Hospital Center, Montréal, Québec, Canada.
  • Piscopo C; Department of Pediatrics and Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Pond DA; U.O.S.C. Medical Genetics, A.O.R.N. "A. Cardarelli", Naples, Italy.
  • Randolph LM; Genomics Medicine Program, Children's Hospital Minnesota, Minneapolis, Minnesota, USA.
  • Rauen KA; Division of Medical Genetics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Rednam S; Department of Pediatrics, Division of Genomic Medicine, UC Davis MIND Institute, Sacramento, California, USA.
  • Rutledge SL; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
  • Saletti V; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Genet Med ; 21(4): 867-876, 2019 04.
Article em En | MEDLINE | ID: mdl-30190611
ABSTRACT

PURPOSE:

Neurofibromatosis type 1 (NF1) is characterized by a highly variable clinical presentation, but almost all NF1-affected adults present with cutaneous and/or subcutaneous neurofibromas. Exceptions are individuals heterozygous for the NF1 in-frame deletion, c.2970_2972del (p.Met992del), associated with a mild phenotype without any externally visible tumors.

METHODS:

A total of 135 individuals from 103 unrelated families, all carrying the constitutional NF1 p.Met992del pathogenic variant and clinically assessed using the same standardized phenotypic checklist form, were included in this study.

RESULTS:

None of the individuals had externally visible plexiform or histopathologically confirmed cutaneous or subcutaneous neurofibromas. We did not identify any complications, such as symptomatic optic pathway gliomas (OPGs) or symptomatic spinal neurofibromas; however, 4.8% of individuals had nonoptic brain tumors, mostly low-grade and asymptomatic, and 38.8% had cognitive impairment/learning disabilities. In an individual with the NF1 constitutional c.2970_2972del and three astrocytomas, we provided proof that all were NF1-associated tumors given loss of heterozygosity at three intragenic NF1 microsatellite markers and c.2970_2972del.

CONCLUSION:

We demonstrate that individuals with the NF1 p.Met992del pathogenic variant have a mild NF1 phenotype lacking clinically suspected plexiform, cutaneous, or subcutaneous neurofibromas. However, learning difficulties are clearly part of the phenotypic presentation in these individuals and will require specialized care.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibroma Plexiforme / Neurofibromina 1 / Deficiências da Aprendizagem Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibroma Plexiforme / Neurofibromina 1 / Deficiências da Aprendizagem Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article